Neuroendokrine Tumoren in der täglichen gastroenterologischen und endoskopischen Praxis – ein klinisch orientierter Leitfaden

Zusammenfassung

Neuroendokrine Tumoren des Gastrointestinaltrakts (GI-NET) sind selten. Die im Vergleich zu den mit hormonellen Syndromen assoziierten funktionellen Tumoren (Insulinom, Gastrinom) häufigeren nichtfunktionellen Tumoren verlaufen klinisch in der Regel bis in späte Stadien indolent. Die Therapie der GI-NET ist multimodal, wobei kurative Therapieansätze aus der vollständigen Entfernung des Tumorgewebes auf endoskopischem respektive chirurgischem Weg bestehen. Patienten in späten Tumorstadien profitieren von interventionell-radiologischen oder medikamentösen Therapieverfahren. Der vorliegende Artikel gibt einen praxisnahen Überblick über die Schlüsselaspekte der Therapie von gastrointestinalen NET in der täglichen gastroenterologischen Praxis mit Schwerpunkt auf endoskopischen Diagnose- und Therapieverfahren.

Abstract

Neuroendocrine tumors of the gastrointestinal tract (GI-NET) are rare tumors. Functional tumors with hormonal syndromes (e. g., insulinoma, gastrinoma) are less common than non-functional tumors, which usually have an indolent course. Therapy for GI-NET is multimodal, including endoscopic or surgical procedures aiming at complete removal of tumor tissue. Patients in later stages may benefit from interventional radiology or medical therapy. This article gives an overview regarding the key aspects of GI-NET therapy in daily gastroenterology practice with emphasis on endoscopic diagnosis and therapy.

Schlüsselwörter

Gastro-entero-pankreatische Tumoren - atrophische Gastritis/Typ-A-Gastritis - Insulinom - Gastrinom

Key words

gastro-entero-pancreatic tumors - atrophic gastritis/Type A-gastritis - insulinoma - gastrinoma

• Literatur

• 1 Bosman FT, Carneiro F, Hruban RH. et al. WHO classification of tumours of the digestive system. World Health Organization; 2010
• 2 Lloyd ROR, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. Lyon, France: International Agency for Research on Cancer (IARC); 2017 4.. Aufl.
• 3 Oberndorfer S. Karzinoide Tumoren des Duenndarmes. Frank Z Pathol 1907; 1: 426-429
• 4 Dasari A, Shen C, Halperin D. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3: 1335-1342 . doi:10.1001/jamaoncol.2017.0589
• 5 Niederle MB, Hackl M, Kaserer K. et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocrine-related cancer 2010; 17: 909-918 . doi:10.1677/ERC-10-0152
• 6 Brierley JGM, Wittekind C. TNM classification of malignant tumours. 8.. Aufl. Chichester, West Sussex, UK; Hoboken, NJ: John Wiley & Sons, Inc; 2017
• 7 https://www.enets.org/1516752000055.d.f.426.pdf
• 8 Teo RYA, Teo TZ, Tai DWM. et al. Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms. Surgery 2019; 165: 672-685 . doi:10.1016/j.surg.2018.10.031
• 9 Clift AK, Faiz O, Goldin R. et al. Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocrine connections 2017; 6: 71-81 . doi:10.1530/EC-16-0114
• 10 Kloppel G. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. Visc Med 2017; 33: 324-330 . doi:10.1159/000481390
• 11 Kloppel G, Couvelard A, Perren A. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90: 162-166 . doi:10.1159/000182196
• 12 Oberg K, Knigge U, Kwekkeboom D. et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2012; 23 (Suppl. 07) vii124-vii130 . doi:10.1093/annonc/mds295
• 13 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13715 carcinoid tumors. Cancer 2003; 97: 934-959 . doi:10.1002/cncr.11105
• 14 Kamp K, Damhuis RA, Feelders RA. et al. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. Endocrine-related cancer 2012; 19: 95-99 . doi:10.1530/ERC-11-0315
• 15 Clift AK, Drymousis P, Al-Nahhas A. et al. Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours. Neuroendocrinology 2015; 102: 26-32 . doi:10.1159/000381716
• 16 Caplin ME, Buscombe JR, Hilson AJ. et al. Carcinoid tumour. Lancet 1998; 352: 799-805 . doi:10.1016/S0140-6736(98)02286-7
• 17 Bornschein J, Kidd M, Malfertheiner P. et al. Gastrointestinal neuroendocrine tumors. Deutsche medizinische Wochenschrift 2008; 133: 1505-1510 . doi:10.1055/s-2008-1081099
• 18 Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid Heart Disease: From Pathophysiology to Treatment – „Something in the Way It Moves“. Neuroendocrinology 2015; 101: 263-273 . doi:10.1159/000381930
• 19 Schott M, Kloppel G, Raffel A. et al. Neuroendocrine neoplasms of the gastrointestinal tract. Deutsches Arzteblatt international 2011; 108: 305-312 . doi:10.3238/arztebl.2011.0305
• 20 Berna MJ, Annibale B, Marignani M. et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. The Journal of clinical endocrinology and metabolism 2008; 93: 1582-1591 . doi:10.1210/jc.2007-2279
• 21 Mosli HH, Dennis A, Kocha W. et al. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. The Journal of clinical endocrinology and metabolism 2012; 97: E1731-E1735 . doi:10.1210/jc.2012-1548
• 22 Turner JJ, Christie PT, Pearce SH. et al. Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). Human mutation 2010; 31: E1089-E1101 . doi:10.1002/humu.21170
• 23 Brandi ML, Gagel RF, Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. The Journal of clinical endocrinology and metabolism 2001; 86: 5658-5671 . doi:10.1210/jcem.86.12.8070
• 24 El SaghirNS, Keating NL, Carlson RW. et al. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book 2014;
• 25 Holzer K. Gastroenteropancreatic neuroendocrine tumors: targeted diagnostics and therapy. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 2014; 85: 731-744 . doi:10.1007/s00104-013-2679-5
• 26 Deutsche Gesellschaft fur Gastroenterologie V-uS, Netzwerk Neuroendokrine Tumoren e. V., Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e. V. et al. Practice guideline neuroendocrine tumors – AWMF-Reg. 021-27. Z Gastroenterol 2018; 56: 583-681 . doi:10.1055/a-0604-2924
• 27 Campana D, Ravizza D, Ferolla P. et al. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine 2016;
• 28 Thomas D, Tsolakis AV, Grozinsky-Glasberg S. et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. European journal of endocrinology/European Federation of Endocrine Societies 2013; 168: 185-193 . doi:10.1530/EJE-12-0836
• 29 Grozinsky-Glasberg S, Thomas D, Strosberg JR. et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth?. World journal of gastroenterology 2013; 19: 8687-8695 . doi:10.3748/wjg.v19.i46.8687
• 30 La Rosa S, Inzani F, Vanoli A. et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Human pathology 2011; 42: 1373-1384 . doi:10.1016/j.humpath.2011.01.018
• 31 Delle Fave G, Kwekkeboom DJ, Van Cutsem E. et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95: 74-87 . doi:10.1159/000335595
• 32 Dixon MF, Genta RM, Yardley JH. et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. The American journal of surgical pathology 1996; 20: 1161-1181
• 33 Basuroy R, Srirajaskanthan R, Prachalias A. et al. Review article: the investigation and management of gastric neuroendocrine tumours. Alimentary pharmacology & therapeutics 2014; 39: 1071-1084 . doi:10.1111/apt.12698
• 34 Hasegawa S, Kobayashi N, Tokuhisa M. et al. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors. Digestion 2017; 96: 13-20 . doi:10.1159/000470838
• 35 Morgat C, Velayoudom-Cephise FL, Schwartz P. et al. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. European journal of nuclear medicine and molecular imaging 2016; 43: 1258-1266 . doi:10.1007/s00259-016-3319-3
• 36 Merola E, Sbrozzi-Vanni A, Panzuto F. et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012; 95: 207-213 . doi:10.1159/000329043
• 37 Uygun A, Kadayifci A, Polat Z. et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. Journal of surgical oncology 2014; 109: 71-74 . doi:10.1002/jso.23477
• 38 Li QL, Zhang YQ, Chen WF. et al. Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World journal of gastroenterology 2012; 18: 5799-5806 . doi:10.3748/wjg.v18.i40.5799
• 39 Campana D, Ravizza D, Ferolla P. et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine 2016; 51: 131-139 . doi:10.1007/s12020-015-0584-z
• 40 Sato Y, Imamura H, Kaizaki Y. et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Digestive endoscopy: official journal of the Japan Gastroenterological Endoscopy Society 2014; 26: 377-384 . doi:10.1111/den.12197
• 41 Sato Y, Takeuchi M, Hashimoto S. et al. Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection. Hepato-gastroenterology 2013; 60: 1524-1529 . doi:10.5754/hge121185
• 42 Sarker S, Gutierrez JP, Council L. et al. Over-the-scope clip-assisted method for resection of full-thickness submucosal lesions of the gastrointestinal tract. Endoscopy 2014; 46: 758-761 . doi:10.1055/s-0034-1365513
• 43 Delle Fave G, O’Toole D, Sundin A. et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology 2016; 103: 119-124 . doi:10.1159/000443168
• 44 Kulke MH, Shah MH, Benson AB. et al. Neuroendocrine tumors, version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN 2015; 13: 78-108
• 45 Falconi M, Eriksson B, Kaltsas G. et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016; 103: 153-171 . doi:10.1159/000443171
• 46 Waddell T, Verheij M, Allum W. et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2013; 24 (Suppl. 06) vi57-vi63 . doi:10.1093/annonc/mdt344
• 47 Fykse V, Sandvik AK, Qvigstad G. et al. Treatment of ECL cell carcinoids with octreotide LAR. Scandinavian journal of gastroenterology 2004; 39: 621-628 . doi:10.1080/00365520410005225
• 48 Fykse V, Sandvik AK, Waldum HL. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scandinavian journal of gastroenterology 2005; 40: 1269-1274
• 49 Jianu CS, Fossmark R, Syversen U. et al. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scandinavian journal of gastroenterology 2011; 46: 456-463 . doi:10.3109/00365521.2010.539255
• 50 Khuroo MS, Khuroo MS, Khuroo NS. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. Journal of gastroenterology and hepatology 2010; 25: 548-554 . doi:10.1111/j.1440-1746.2009.06131.x
• 51 Garcia-Carbonero R, Sorbye H, Baudin E. et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 2016; 103: 186-194 . doi:10.1159/000443172
• 52 Scherubl H, Jensen RT, Cadiot G. et al. Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World journal of gastrointestinal endoscopy 2010; 2: 325-334 . doi:10.4253/wjge.v2.i10.325
• 53 Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best practice & research Clinical gastroenterology 2005; 19: 675-697 . doi:10.1016/j.bpg.2005.05.009
• 54 Gincul R, Ponchon T, Napoleon B. et al. Endoscopic treatment of sporadic small duodenal and ampullary neuroendocrine tumors. Endoscopy 2016;
• 55 Donow C, Pipeleers-Marichal M, Schroder S. et al. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer 1991; 68: 1329-1334
• 56 Randle RW, Ahmed S, Newman NA. et al. Clinical outcomes for neuroendocrine tumors of the duodenum and ampulla of Vater: a population-based study. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 2014; 18: 354-362 . doi:10.1007/s11605-013-2365-4
• 57 Vanoli A, La Rosa S, Klersy C. et al. Four Neuroendocrine Tumor Types and the Neuroendocrine Carcinoma of the Duodenum. Analysis of 203 Cases. Neuroendocrinology 2016;
• 58 Sadowski SM, Neychev V, Millo C. et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016; 34: 588-596 . doi:10.1200/JCO.2015.64.0987
• 59 Kim GH, Kim JI, Jeon SW. et al. Endoscopic resection for duodenal carcinoid tumors: a multicenter, retrospective study. Journal of gastroenterology and hepatology 2014; 29: 318-324 . doi:10.1111/jgh.12390
• 60 Kyuno D, Ohno K, Katsuki S. et al. Laparoscopic-endoscopic cooperative surgery is a safe and effective treatment for superficial nonampullary duodenal tumors. Asian J Endosc Surg 2015; 8: 461-464 . doi:10.1111/ases.12211
• 61 Pape UF, Maasberg S, Jann H. et al. Management of follow-up of neuroendocrine neoplasias. Best practice & research Clinical endocrinology & metabolism 2016; 30: 129-140 . doi:10.1016/j.beem.2016.02.001
• 62 Haug AR, Cindea-Drimus R, Auernhammer CJ. et al. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology 2014; 270: 517-525 . doi:10.1148/radiol.13122501
• 63 de Herder WW, Niederle B, Scoazec JY. et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 183-188 . doi:10.1159/000098010
• 64 Jensen RT, Niederle B, Mitry E. et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173-182 . doi:10.1159/000098009
• 65 O’Toole D, Salazar R, Falconi M. et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006; 84: 189-195 . doi:10.1159/000098011
• 66 Thomas-Marques L, Murat A, Delemer B. et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. The American journal of gastroenterology 2006; 101: 266-273 . doi:10.1111/j.1572-0241.2006.00367.x
• 67 Rosch T, Lightdale CJ, Botet JF. et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. The New England journal of medicine 1992; 326: 1721-1726 . doi:10.1056/NEJM199206253262601
• 68 Anderson MA, Carpenter S, Thompson NW. et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. The American journal of gastroenterology 2000; 95: 2271-2277 . doi:10.1111/j.1572-0241.2000.02480.x
• 69 Dietrich CF, Sahai AV, D’Onofrio M. et al. Differential diagnosis of small solid pancreatic lesions. Gastrointestinal endoscopy 2016;
• 70 Kitano M, Kudo M, Yamao K. et al. Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography. The American journal of gastroenterology 2012; 107: 303-310 . doi:10.1038/ajg.2011.354
• 71 Bang JY, Hebert-Magee S, Trevino J. et al. Randomized trial comparing the 22-gauge aspiration and 22-gauge biopsy needles for EUS-guided sampling of solid pancreatic mass lesions. Gastrointestinal endoscopy 2012; 76: 321-327 . doi:10.1016/j.gie.2012.03.1392
• 72 Ramesh J, Bang JY, Hebert-Magee S. et al. Randomized Trial Comparing the Flexible 19G and 25G Needles for Endoscopic Ultrasound-Guided Fine Needle Aspiration of Solid Pancreatic Mass Lesions. Pancreas 2015; 44: 128-133 . doi:10.1097/MPA.0000000000000217
• 73 Weynand B, Borbath I, Bernard V. et al. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index. Cytopathology: official journal of the British Society for Clinical Cytology 2014; 25: 389-395 . doi:10.1111/cyt.12111
• 74 Chantarojanasiri T, Hirooka Y, Kawashima H. et al. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone versus the combination. Endoscopy international open 2017; 5: E1136-E1143 . doi:10.1055/s-0043-118829
• 75 van Asselt SJ, Brouwers AH, van Dullemen HM. et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointestinal endoscopy 2015; 81: 159-167 e152 . doi:10.1016/j.gie.2014.09.037
• 76 Tamagno G, Scherer V, Caimo A. et al. Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study. Digestion 2018; 98: 112-118 . doi:10.1159/000487939
• 77 Qiu W, Christakis I, Silva A. et al. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clinical endocrinology 2016; 85: 400-407 . doi:10.1111/cen.13119
• 78 Sundin A, Vullierme MP, Kaltsas G. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-183 . doi:10.1159/000184855
• 79 Sharma P, Arora S, Dhull VS. et al. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Abdominal imaging 2015; 40: 299-309 . doi:10.1007/s00261-014-0219-5
• 80 Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN. et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. European journal of nuclear medicine and molecular imaging 2013; 40: 897-907 . doi:10.1007/s00259-013-2371-5
• 81 Hoeffel C, Job L, Ladam-Marcus V. et al. Detection of hepatic metastases from carcinoid tumor: prospective evaluation of contrast-enhanced ultrasonography. Digestive diseases and sciences 2009; 54: 2040-2046 . doi:10.1007/s10620-008-0570-x
• 82 Park H, Choi JH, Oh D. et al. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study. Clinical endoscopy 2015; 48: 158-164 . doi:10.5946/ce.2015.48.2.158
• 83 Armellini E, Crino SF, Ballare M. et al. Endoscopic ultrasound-guided ethanol ablation of pancreatic neuroendocrine tumours: A case study and literature review. World journal of gastrointestinal endoscopy 2016; 8: 192-197 . doi:10.4253/wjge.v8.i3.192
• 84 Rossi S, Viera FT, Ghittoni G. et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas 2014; 43: 938-945 . doi:10.1097/MPA.0000000000000133
• 85 Pai M, Habib N, Senturk H. et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World journal of gastrointestinal surgery 2015; 7: 52-59 . doi:10.4240/wjgs.v7.i4.52
• 86 Sallinen V, Le Large TY, Galeev S. et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors – a systematic review and meta-analysis. HPB (Oxford) 2017; 19: 310-320 . doi:10.1016/j.hpb.2016.12.010
• 87 Raymond E, Dahan L, Raoul JL. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England journal of medicine 2011; 364: 501-513 . doi:10.1056/NEJMoa1003825
• 88 Yao JC, Shah MH, Ito T. et al. Everolimus for advanced pancreatic neuroendocrine tumors. The New England journal of medicine 2011; 364: 514-523 . doi:10.1056/NEJMoa1009290
• 89 Pavel M, O’Toole D, Costa F. et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016; 103: 172-185 . doi:10.1159/000443167
• 90 Mehrabi A, Fischer L, Hafezi M. et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 2014; 43: 675-686 . doi:10.1097/MPA.0000000000000110
• 91 McLean AM, Fairclough PD. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best practice & research Clinical endocrinology & metabolism 2005; 19: 177-193 . doi:10.1016/j.beem.2004.11.012
• 92 Sotoudehmanesh R, Hedayat A, Shirazian N. et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine 2007; 31: 238-241
• 93 Kann PH, Moll R, Bartsch D. et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: Indications and clinical relevance in a single investigator cohort of 47 patients. Endocrine 2017; 56: 158-163 . doi:10.1007/s12020-016-1179-z
• 94 Jensen RT, Cadiot G, Brandi ML. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119 . doi:10.1159/000335591
• 95 Nockel P, Babic B, Millo C. et al. Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan. The Journal of clinical endocrinology and metabolism 2017; 102: 195-199 . doi:10.1210/jc.2016-3445
• 96 Prasad V, Sainz-Esteban A, Arsenic R. et al. Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. European journal of nuclear medicine and molecular imaging 2016; 43: 1593-1600 . doi:10.1007/s00259-016-3331-7
• 97 Kauhanen S, Seppanen M, Minn H. et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. The Journal of clinical endocrinology and metabolism 2007; 92: 1237-1244 . doi:10.1210/jc.2006-1479
• 98 Wild D, Macke H, Christ E. et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. The New England journal of medicine 2008; 359: 766-768 . doi:10.1056/NEJMc0802045
• 99 Luo Y, Pan Q, Yao S. et al. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2016; 57: 715-720 . doi:10.2967/jnumed.115.167445
• 100 Lin XZ, Wu ZY, Tao R. et al. Dual energy spectral CT imaging of insulinoma-Value in preoperative diagnosis compared with conventional multi-detector CT. European journal of radiology 2012; 81: 2487-2494 . doi:10.1016/j.ejrad.2011.10.028
• 101 Lakhtakia S, Ramchandani M, Galasso D. et al. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointestinal endoscopy 2016; 83: 234-239 . doi:10.1016/j.gie.2015.08.085
• 102 Qin SY, Lu XP, Jiang HX. EUS-guided ethanol ablation of insulinomas: case series and literature review. Medicine 2014; 93: e85 . doi:10.1097/MD.0000000000000085
• 103 Jann H, Roll S, Couvelard A. et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117: 3332-3341 . doi:10.1002/cncr.25855
• 104 Niederle MB, Niederle B. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. The oncologist 2011; 16: 602-613 . doi:10.1634/theoncologist.2011-0002
• 105 Bellutti M, Fry LC, Schmitt J. et al. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Digestive diseases and sciences 2009; 54: 1050-1058 . doi:10.1007/s10620-008-0456-y
• 106 Pennazio M, Spada C, Eliakim R. et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2015; 47: 352-376 . doi:10.1055/s-0034-1391855
• 107 Zagorowicz ES, Pietrzak AM, Wronska E. et al. Small bowel tumors detected and missed during capsule endoscopy: single center experience. World journal of gastroenterology 2013; 19: 9043-9048 . doi:10.3748/wjg.v19.i47.9043
• 108 Frilling A, Smith G, Clift AK. et al. Capsule endoscopy to detect primary tumour site in metastatic neuroendocrine tumours. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2014; 46: 1038-1042 . doi:10.1016/j.dld.2014.07.004
• 109 Singeap AM, Trifan A, Cojocariu C. et al. Outcomes after symptomatic capsule retention in suspected small bowel obstruction. European journal of gastroenterology & hepatology 2011; 23: 886-890 . doi:10.1097/MEG.0b013e328349efa4
• 110 Rossi RE, Conte D, Elli L. et al. Endoscopic techniques to detect small-bowel neuroendocrine tumors: A literature review. United European gastroenterology journal 2017; 5: 5-12 . doi:10.1177/2050640616658220
• 111 Cangemi DJ, Patel MK, Gomez V. et al. Small bowel tumors discovered during double.balloon enteroscopy: analysis of a large prospectively collected single-center database. J Clin Gastroenterol 2013; 47: 769-772 . doi:10.1097/MCG.0b013e318281a44e
• 112 Arnold R, Wilke A, Rinke A. et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2008; 6: 820-827 . doi:10.1016/j.cgh.2008.02.052
• 113 Pape UF, Perren A, Niederle B. et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95: 135-156 . doi:10.1159/000335629
• 114 Niederle B, Pape UF, Costa F. et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016; 103: 125-138 . doi:10.1159/000443170
• 115 Ardill JE, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocrine-related cancer 2003; 10: 459-462
• 116 Feldman JM, O’Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. The American journal of medicine 1986; 81: 41-48
• 117 Bhattacharyya S, Toumpanakis C, Caplin ME. et al. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. The American journal of cardiology 2008; 102: 938-942 . doi:10.1016/j.amjcard.2008.05.047
• 118 Arnold R, Chen YJ, Costa F. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90: 227-233 . doi:10.1159/000225952
• 119 Baum RP, Prasad V, Hommann M. et al. Receptor PET/CT imaging of neuroendocrine tumors. Recent results in cancer research. Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2008; 170: 225-242
• 120 Kulemann V, Schima W, Tamandl D. et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?. European journal of radiology 2011; 79: e1-e6 . doi:10.1016/j.ejrad.2010.03.004
• 121 Mayerhoefer ME, Ba-Ssalamah A, Weber M. et al. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. European radiology 2013; 23: 1978-1985 . doi:10.1007/s00330-013-2785-2
• 122 Berzaczy D, Giraudo C, Haug AR. et al. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clinical nuclear medicine 2017; 42: 669-674 . doi:10.1097/RLU.0000000000001753
• 123 Landerholm K, Zar N, Andersson RE. et al. Survival and prognostic factors in patients with small bowel carcinoid tumour. The British journal of surgery 2011; 98: 1617-1624 . doi:10.1002/bjs.7649
• 124 Landry CS, Lin HY, Phan A. et al. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World journal of surgery 2013; 37: 1695-1700 . doi:10.1007/s00268-013-1918-8
• 125 Schindl M, Kaczirek K, Passler C. et al. Treatment of small intestinal neuroendocrine tumors: is an extended multimodal approach justified?. World journal of surgery 2002; 26: 976-984 . doi:10.1007/s00268-002-6628-6
• 126 Capurso G, Rinzivillo M, Bettini R. et al. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. The British journal of surgery 2012; 99: 1480-1486 . doi:10.1002/bjs.8842
• 127 Rinke A, Wittenberg M, Schade-Brittinger C. et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology 2017; 104: 26-32 . doi:10.1159/000443612
• 128 Caplin ME, Pavel M, Cwikla JB. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. The New England journal of medicine 2014; 371: 224-233 . doi:10.1056/NEJMoa1316158
• 129 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England journal of medicine 2017; 376: 125-135 . doi:10.1056/NEJMoa1607427
• 130 Yao JC, Fazio N, Singh S. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968-977 . doi:10.1016/S0140-6736(15)00817-X
• 131 Pape UF, Berndt U, Muller-Nordhorn J. et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-related cancer 2008; 15: 1083-1097 . doi:10.1677/ERC-08-0017
• 132 Modlin IM, Kidd M, Latich I. et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751
• 133 Alexandraki KI, Kaltsas GA, Grozinsky-Glasberg S. et al. Appendiceal neuroendocrine neoplasms: diagnosis and management. Endocrine-related cancer 2016; 23: R27-R41 . doi:10.1530/ERC-15-0310
• 134 Rossi RE, Luong TV, Caplin ME. et al. Goblet cell appendiceal tumors--management dilemmas and long-term outcomes. Surgical oncology 2015; 24: 47-53 . doi:10.1016/j.suronc.2015.01.001
• 135 Toumpanakis C, Standish RA, Baishnab E. et al. Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. Diseases of the colon and rectum 2007; 50: 315-322 . doi:10.1007/s10350-006-0762-4
• 136 Pape UF, Niederle B, Costa F. et al. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology 2016; 103: 144-152 . doi:10.1159/000443165
• 137 Kleiman DA, Finnerty B, Beninato T. et al. Features Associated With Metastases Among Well-Differentiated Neuroendocrine (Carcinoid) Tumors of the Appendix: The Significance of Small Vessel Invasion in Addition to Size. Diseases of the colon and rectum 2015; 58: 1137-1143 . doi:10.1097/DCR.0000000000000492
• 138 Masselli G, Gualdi G. CT and MR enterography in evaluating small bowel diseases: when to use which modality?. Abdominal imaging 2013; 38: 249-259 . doi:10.1007/s00261-012-9961-8
• 139 Caplin M, Sundin A, Nillson O. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012; 95: 88-97 . doi:10.1159/000335594
• 140 Murray SE, Lloyd RV, Sippel RS. et al. Clinicopathologic characteristics of colonic carcinoid tumors. The Journal of surgical research 2013; 184: 183-188 . doi:10.1016/j.jss.2013.05.107
• 141 Al Natour RH, Saund MS, Sanchez VM. et al. Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 2012; 16: 595-602 . doi:10.1007/s11605-011-1786-1
• 142 Salyers WJ, Vega KJ, Munoz JC. et al. Neuroendocrine tumors of the gastrointestinal tract: Case reports and literature review. World journal of gastrointestinal oncology 2014; 6: 301-310 . doi:10.4251/wjgo.v6.i8.301
• 143 Ramage JK, De Herder WW, Delle Fave G. et al. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology 2016; 103: 139-143 . doi:10.1159/000443166
• 144 Kunz PL, Reidy-Lagunes D, Anthony LB. et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013; 42: 557-577 . doi:10.1097/MPA.0b013e31828e34a4
• 145 Hope TA, Pampaloni MH, Nakakura E. et al. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdominal imaging 2015; 40: 1432-1440 . doi:10.1007/s00261-015-0409-9
• 146 Caplin ME, Pavel M, Cwikla JB. et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocrine-related cancer 2016; 23: 191-199 . doi:10.1530/ERC-15-0490
• 147 Janson ET, Sorbye H, Welin S. et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta oncologica 2014; 53: 1284-1297 . doi:10.3109/0284186X.2014.941999
• 148 Jetmore AB, Ray JE, Gathright Jr JB. et al. Rectal carcinoids: the most frequent carcinoid tumor. Diseases of the colon and rectum 1992; 35: 717-725
• 149 Chi Y, Du F, Zhao H. et al. Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors. World journal of gastroenterology 2014; 20: 16252-16257 . doi:10.3748/wjg.v20.i43.16252
• 150 Jernman J, Valimaki MJ, Louhimo J. et al. The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours. Neuroendocrinology 2012; 95: 317-324 . doi:10.1159/000333035
• 151 Higaki S, Nishiaki M, Mitani N. et al. Effectiveness of local endoscopic resection of rectal carcinoid tumors. Endoscopy 1997; 29: 171-175 . doi:10.1055/s-2007-1004158
• 152 Lee SP, Sung IK, Kim JH. et al. The effect of preceding biopsy on complete endoscopic resection in rectal carcinoid tumor. Journal of Korean medical science 2014; 29: 512-518 . doi:10.3346/jkms.2014.29.4.512
• 153 Kobayashi K, Katsumata T, Yoshizawa S. et al. Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. Diseases of the colon and rectum 2005; 48: 285-291 . doi:10.1007/s10350-004-0765-y
• 154 Kim JH, Moon W, Park SJ. et al. Clinical impact of endoscopic ultrasonography for small rectal neuroendocrine tumors. The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology 2014; 25: 657-660 . doi:10.5152/tjg.2014.6647
• 155 Park CH, Cheon JH, Kim JO. et al. Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy 2011; 43: 790-795 . doi:10.1055/s-0030-1256414
• 156 Gleeson FC, Levy MJ, Dozois EJ. et al. Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes. Gastrointestinal endoscopy 2014; 80: 144-151 . doi:10.1016/j.gie.2013.11.031
• 157 Nasseri Y, Langenfeld SJ. Imaging for Colorectal Cancer. The Surgical clinics of North America 2017; 97: 503-513 . doi:10.1016/j.suc.2017.01.002
• 158 Basuroy R, Haji A, Ramage JK. et al. Review article: the investigation and management of rectal neuroendocrine tumours. Alimentary pharmacology & therapeutics 2016; 44: 332-345 . doi:10.1111/apt.13697
• 159 Zhou X, Xie H, Xie L. et al. Endoscopic resection therapies for rectal neuroendocrine tumors: a systematic review and meta-analysis. Journal of gastroenterology and hepatology 2014; 29: 259-268 . doi:10.1111/jgh.12395
• 160 Sung HY, Kim SW, Kang WK. et al. Long-term prognosis of an endoscopically treated rectal neuroendocrine tumor: 10-year experience in a single institution. European journal of gastroenterology & hepatology 2012; 24: 978-983 . doi:10.1097/MEG.0b013e3283551e0b
• 161 Park HW, Byeon JS, Park YS. et al. Endoscopic submucosal dissection for treatment of rectal carcinoid tumors. Gastrointestinal endoscopy 2010; 72: 143-149 . doi:10.1016/j.gie.2010.01.040
• 162 Lee DS, Jeon SW, Park SY. et al. The feasibility of endoscopic submucosal dissection for rectal carcinoid tumors: comparison with endoscopic mucosal resection. Endoscopy 2010; 42: 647-651 . doi:10.1055/s-0030-1255591
• 163 Jeon JH, Cheung DY, Lee SJ. et al. Endoscopic resection yields reliable outcomes for small rectal neuroendocrine tumors. Digestive endoscopy: official journal of the Japan Gastroenterological Endoscopy Society 2014; 26: 556-563 . doi:10.1111/den.12232
• 164 Kim GU, Kim KJ, Hong SM. et al. Clinical outcomes of rectal neuroendocrine tumors </= 10 mm following endoscopic resection. Endoscopy 2013; 45: 1018-1023 . doi:10.1055/s-0033-1344860
• 165 Klare P, Burlefinger R, Neu B. et al. Over-the-scope clip-assisted endoscopic full-thickness resection after incomplete resection of a rectal neuroendocrine tumor. Endoscopy 2015; 47 (Suppl. 01) E47-E48 . doi:10.1055/s-0034-1391301
• 166 Weinstock B, Ward SC, Harpaz N. et al. Clinical and prognostic features of rectal neuroendocrine tumors. Neuroendocrinology 2013; 98: 180-187 . doi:10.1159/000355612